Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 202

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients

Open access
Wang, Peilu, Bahreini, Amir, Gyanchandani, Rekha, Lucas, Peter C., Hartmaier, Ryan J., Watters, Rebecca J., Jonnalagadda, Amruth R., Trejo Bittar, Humberto E., Berg, Aaron, Hamilton, Ronald L., Kurland, Brenda F., Weiss, Kurt R., Mathew, Aju, Leone, Jose Pablo, Davidson, Nancy E., Nikiforova, Marina N., Brufsky, Adam M., Ambros, Tadeu F., Stern, Andrew M., Puhalla, Shannon L., Lee, Adrian V., Oesterreich, Steffi · 2016 · Clinical Cancer Research

Abstract

Purpose: Given the clinical relevance of ESR1 mutations as potential drivers of resistance to endocrine therapy, this study used sensitive detection methods to determine the frequency of ESR1 mutations in primary and metastatic breast cancer, and in cell-free DNA (cfDNA). Experimental Design: Six ESR1 mutations (K303R, S463P, Y537C, Y537N, Y537S, D538G) were assessed by digital droplet PCR (ddPCR), with lower limits of detection of 0.05% to 0.16%, in primary tumors (n = 43), bone (n = 12) and brain metastases (n = 38), and cfDNA (n = 29). Correlations between ESR1 mutations in metastatic lesions and single (1 patient) or serial blood draws (4 patients) were assessed. Results: ESR1 mutations were detected for D538G (n = 13), Y537S (n = 3), and Y537C (n = 1), and not for K303R, S463P, or Y537N. Mutation rates were 7.0% (3/43 primary tumors), 9.1% (1/11 bone metastases), 12.5% (3/24 brain metastases), and 24.1% (7/29 cfDNA). Two patients showed polyclonal disease with more than one ESR1 mutation. Mutation allele frequencies were 0.07% to 0.2% in primary tumors, 1.4% in bone metastases, 34.3% to 44.9% in brain metastases, and 0.2% to 13.7% in cfDNA. In cases with both cfDNA and metastatic samples (n = 5), mutations were detected in both (n = 3) or in cfDNA only (n = 2). Treatment was associated with changes in ESR1 mutation detection and allele frequency. Conclusions: ESR1 mutations were detected at very low allele frequencies in some primary breast cancers, and at high allele frequency in metastases, suggesting that in some tumors rare ESR1-mutant clones are enriched by endocrine therapy. Further studies should address whether sensitive detection of ESR1 mutations in primary breast cancer and in serial blood draws may be predictive for development of resistant disease. Clin Cancer Res; 22(5); 1130–7. ©2015 AACR. See related commentary by Gu and Fuqua, p. 1034

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-1534

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 202

Metadata

Authors
Wang, P., Bahreini, A., Gyanchandani, R., Lucas, P. C., Hartmaier, R. J., Watters, R. J., Jonnalagadda, A. R., Trejo Bittar, H. E., Berg, A., Hamilton, R. L., Kurland, B. F., Weiss, K. R., Mathew, A., Leone, J. P., Davidson, N. E., Nikiforova, M. N., Brufsky, A. M., Ambros, T. F., Stern, A. M., Puhalla, S. L., Lee, A. V., & Oesterreich, S.
Venue
Clinical Cancer Research
Published
2016-02-29
Volume
22
Issue
5
Pages
1130-1137
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W1934888046
Cited by
202
References
5
FWCI
8.05
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-1534
The paper
Wang, P., Bahreini, A., Gyanchandani, R., Lucas, P. C., Hartmaier, R. J., Watters, R. J., Jonnalagadda, A. R., Trejo Bittar, H. E., Berg, A., Hamilton, R. L., Kurland, B. F., Weiss, K. R., Mathew, A., Leone, J. P., Davidson, N. E., Nikiforova, M. N., Brufsky, A. M., Ambros, T. F., Stern, A. M., . . . Oesterreich, S. (2016). Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-1534

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.